Evidence map›Paper›PMID 30666440›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2019

Correlation between the duration of locoregional control and survival in T1-T2 oropharyngeal cancer patients.

Alexandre Caula, Marc Boukhris, Joanne Guerlain, Yungan Tao, Ingrid Breuskin, Haitham Mirghani, Stéphane Temam, Philippe Gorphe

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandre CaulaDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Marc BoukhrisDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Joanne GuerlainDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Yungan TaoDepartment of Radiotherapy, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
Ingrid BreuskinDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Haitham MirghaniDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Stéphane TemamDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France.
Philippe GorpheDepartment of Head and Neck Oncology, Gustave Roussy Institute, Université Paris-Saclay, 14 rue Edouard Vaillant, 94800, Villejuif, France. Philippe.gorphe@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-7604-4964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the correlation between the time to locoregional recurrence and survival in T1-T2 oropharyngeal squamous-cell carcinoma (OPSCC) patients.

methodsA retrospective, single-site study of patients with T1-T2 OPSCC treated with curative intent between 2000 and 2015 who had a locoregional recurrence without distant metastases. Patients without a disease-free interval (i.e., persistent macroscopic disease after the end of treatment and a time to locoregional recurrence of less than 3 months) were excluded. The endpoint considered was overall survival (OS).

resultsOut of 602 T1-T2 OPSCC patients, 121 patients had a locoregional recurrence and they were, hence, analyzed. All of the patients were heavy-smokers, with a consumption of more than 20 pack-years. The recurrence was local in 59.5%, regional in 27.3%, and both local and regional in 13.2% of the patients. The median time to locoregional recurrence and median OS was 15 months and 44 months, respectively. The time to locoregional recurrence was correlated with OS (p < 0.0001). In multivariate analyses, factors associated with survival were an initial N0-N2a versus N2b-N3 nodal staging and a 12-month threshold for the time to locoregional recurrence.

conclusionsLocoregional control in T1-T2 OPSCC is not only a qualitative prognostic factor but also a quantitative prognostic factor of survival. A time to locoregional recurrence of less than 12 months was correlated with an unfavorable prognosis.

Indexed as

Carcinoma, Squamous CellNeoplasm Recurrence, LocalOropharyngeal NeoplasmsAdultAgedFemaleFranceHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRisk FactorsSmokingSurvival AnalysisDisease-free intervalLocoregional recurrenceOropharyngeal neoplasmsSurvival

Identifiers

PMID30666440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.